Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback
Industry Focus - Ein Podcast von The Motley Fool
Kategorien:
Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.
